JNJ-101556143 clinical trials
JNJ-101556143 is named as an intervention in 4 current clinical trials in our USA, Australia, China, Japan, Israel, Spain and France registers. 4 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Janssen Research & Development, LLC. The most-studied condition is Prostatic Neoplasms.
Patient leaflets for JNJ-101556143
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of JNJ-101556143
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
NCT07906717 · ClinicalTrials.gov ↗ · Prostatic Neoplasms
|
Phase 3 | Recruiting | Janssen Research & Development, LLC | USA, Israel |
|
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
NCT07832292 · Prostatic Neoplasms
|
Phase 2 | Recruiting | Janssen Research & Development, LLC | USA, China, Japan, Australia |
|
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683 · Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
|
Phase 1 | Recruiting | Janssen Research & Development, LLC | USA, Spain, Australia |
|
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089 · Prostatic Neoplasms
|
Phase 1 | Recruiting | Janssen Research & Development, LLC | USA, China, France, Japan, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with JNJ-101556143
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 4 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 4 | 4 |
| Clinical trials in Australia | 3 | 3 |
| Clinical trials in China | 2 | 2 |
| Clinical trials in Japan | 2 | 2 |
| Clinical trials in Israel | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about JNJ-101556143 trials
How many clinical trials are testing JNJ-101556143?
4 current trials in our USA, Australia, China, Japan, Israel, Spain and France registers name JNJ-101556143 (also registered as HLD-0915) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are JNJ-101556143 trials recruiting patients?
Yes. 4 of the 4 trials are recruiting: 4 with sites in USA, 3 with sites in Australia, 2 with sites in China, 2 with sites in Japan, 1 with sites in Israel, 1 with sites in Spain and 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors JNJ-101556143 clinical trials?
The lead sponsor is Janssen Research & Development, LLC. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how JNJ-101556143 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how JNJ-101556143 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists JNJ-101556143 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.